The conversation discusses experiences with PRP and mesotherapy for hair loss. One user mentions both treatments were costly without significant results.
A user in Indonesia is seeking legitimate RU58841 due to local availability issues and considers using Ubuy for international shipping. Another user suggests checking seller ratings and product details on Ubuy and mentions that specialized forums or international suppliers might also be helpful.
The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.
The conversation is about finding ethanol in California for mixing with RU58841 for hair loss treatment. Users suggest alternatives like high-proof alcohol from liquor stores or purchasing lab-grade ethanol online.
The conversation discusses the use of RU58841 for hair loss, focusing on its side effects, standardization issues, and user experiences. The user also inquires about the use of other treatments like minoxidil, finasteride, and microneedling.
The conversation discusses a hair loss treatment regimen including oral dutasteride, oral minoxidil, tadalafil, and the recent addition of RU58841. The user shares experiences with these treatments, noting significant hair regrowth and stabilization, and discusses the cost and preparation of RU58841.
Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.
The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
The conversation is about starting a hair loss treatment using a topical solution containing RU58841, Minoxidil, and Copper Peptides. The user plans to test the product and share updates on its effectiveness.
RU58841 cured seborrheic dermatitis, oily scalp, dandruff, and scalp pain, improving hair health when combined with Minoxidil. Another user noted diet impacts their seborrheic dermatitis and that finasteride hasn't changed their condition.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.
RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.
An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.
The conversation is about finding a source for RU58841 as a substitute for finasteride for hair loss treatment. Suggestions include Amazon and Anageninc.com.
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.
Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
An 18-year-old is seeking advice on microneedling while using RU58841 for hair loss. Recommendations include using a derma pen with 0.5mm needles every two weeks and avoiding RU application for 24 hours post-microneedling to prevent absorption into the bloodstream.
Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.